Furosemide is under clinical development by scPharmaceuticals and currently in Pre-Registration for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Pre-Registration drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Furosemide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Furosemide overview
Furosemide (Furoscix) is a sulfamoylanthranilic acid derivative, acts as a diuretic agent. It is formulated as an injectable solution for the subcutaneous route of administration. Furoscix is indicated for the treatment of congestion due to fluid overload in adult patients with new york heart association (NYHA) class ii and class iii chronic heart failure.
Furosemide is indicated for edema and fluid overload in patients with chronic heart failure and acutely decompensated heart failure. The drug candidate is formulated as a solution for injection and administered through subcutaneous route. It is delivered using micropump based on Sensile Medical’s SensePatch drug delivery technology. The drug candidate is Na-K-Cl cotransporter2 (NKCC2) inhibitor. It is under development for the treatment of NYHA Class IV heart failure and edema due to fluid overload in patients with chronic kidney disease, or CKD.
ScPharmaceuticals overview
scPharmaceuticals is a pharmaceutical company that specializes in the development and commercialization of innovative outpatient care solutions. It primarily focuses on the management of acute conditions such as worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product is a proprietary formulation of a diuretic for subcutaneous administration, designed for the treatment of congestion due to fluid overload in adult patients with certain classes of heart failure. The company’s brand, FUROSCIX (furosemide injection), is an investigational drug-device combination product featuring a fixed dose auto-injector designed to administer a single dose of furosemide. scPharmaceuticals‘ products are targeted towards patient populations and disease states where outpatient management can have the greatest impact. The company operates in the US. scPharmaceuticals is headquartered in Burlington, Massachusetts, the US.
For a complete picture of Furosemide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
